Selpercatinib

Generic Name
Selpercatinib
Brand Names
Retevmo, Retsevmo
Drug Type
Small Molecule
Chemical Formula
C29H31N7O3
CAS Number
2152628-33-4
Unique Ingredient Identifier
CEGM9YBNGD
Background

Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including cabozantinib, ponatinib, sorafenib, sunitinib, and vandetanib, have shown efficacy in RET-dri...

Indication

Selpercatinib is approved to treat:

Selpercatinib is currently approved for these indications under an accelerated approval scheme and continued approval may be contingent on future confirmatory trials.

Associated Conditions
Locally Advanced Solid Neoplasm, Metastatic Solid Neoplasm, Advanced RET-fusion thyroid cancer, Advanced RET-mutant medullary thyroid cancer, Metastatic RET-fusion Non Small Cell Lung Cancer, Metastatic RET-fusion thyroid cancer, Metastatic RET-mutant medullary thyroid cancer
Associated Therapies
-

A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2023-06-18
Last Posted Date
2024-01-05
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
32
Registration Number
NCT05906836
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Labcorp Clinical Research LP, Dallas, Texas, United States

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

First Posted Date
2022-12-30
Last Posted Date
2024-12-12
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
30
Registration Number
NCT05668962
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Michigan, Ann Arbor, Michigan, United States

๐Ÿ‡บ๐Ÿ‡ธ

MedStar Washington Hospital Center, Washington, D.C., District of Columbia, United States

๐Ÿ‡บ๐Ÿ‡ธ

Moffitt Cancer Center, Tampa, Florida, United States

and more 3 locations

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-11-29
Last Posted Date
2022-11-29
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
32
Registration Number
NCT05630274
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Celerion, Tempe, Arizona, United States

A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-11-29
Last Posted Date
2022-11-29
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
12
Registration Number
NCT05630287
Locations
๐Ÿ‡บ๐Ÿ‡ธ

LabCorp CRU, Inc., Madison, Wisconsin, United States

A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-07-21
Last Posted Date
2022-07-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
13
Registration Number
NCT05469113
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Celerion, Tempe, Arizona, United States

A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-07-21
Last Posted Date
2022-07-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
19
Registration Number
NCT05468164
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Celerion, Tempe, Arizona, United States

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-07-21
Last Posted Date
2022-07-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
37
Registration Number
NCT05469100
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Orange County Research Center, Tustin, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Stanford Health Care, Valley Care Program, Pleasanton, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Anaheim Regional Center, Anaheim, California, United States

and more 3 locations

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-06-29
Last Posted Date
2023-04-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
25
Registration Number
NCT05436912
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Orange County Research Center, Tustin, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Orange County Research Institute, Anaheim, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Riverside Clinical Research, Edgewater, Florida, United States

and more 4 locations

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

First Posted Date
2022-05-06
Last Posted Date
2024-07-09
Lead Sponsor
SWOG Cancer Research Network
Registration Number
NCT05364645
Locations
๐Ÿ‡บ๐Ÿ‡ธ

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Sutter Auburn Faith Hospital, Auburn, California, United States

and more 262 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath